Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma — Stella

Home/Advanced Lung Adenocarcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Advanced Lung Adenocarcinoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Texas Health Science Center at San Antonio, San Antonio, Texas

Key details

Phase

Early testing / Safety & dosing

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

National Cancer Institute (NCI)

Enrollment target

~44 participants

Started

December 2024

Primary completion

September 2027

Age range

18 Years and older

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.